This phase 3 pooled post hoc analysis assessed how quickly and how completely abrocitinib 100 mg or 200 mg achieved the combined endpoint of EASI-90 plus itch-free/near-itch-free state (PP-NRS 0–1) in adults with moderate-to-severe atopic dermatitis across JADE DARE, JADE COMPARE, and JADE EXTEND trials, including patients who previously failed dupilumab.
By week 2 in JADE DARE, abrocitinib 200 mg achieved EASI-90 + PP-NRS0/1 in 5.8% vs. 1.1% with dupilumab. At week 16 in JADE COMPARE, rates were 27.1% (abrocitinib 200 mg), 20.2% (abrocitinib 100 mg), 15.5% (dupilumab), and 5.4% (placebo). Among prior dupilumab non-responders in JADE EXTEND, 16.7% on abrocitinib 200 mg and 18.5% on 100 mg achieved this combined endpoint.
Post hoc analysis limits causal inference. Sample sizes for subgroups (e.g., dupilumab inadequate responders) were not reported, reducing precision. Rates of the stringent combined endpoint are low overall, making cross-trial comparisons difficult.
For patients with moderate-to-severe atopic dermatitis who have not responded to dupilumab, switching to abrocitinib—particularly 200 mg—can still achieve near-complete skin clearance with itch freedom in a meaningful subset. Early response (by week 2) favors abrocitinib 200 mg over dupilumab.
Explore related topics
